This statistic depicts small molecule sales at risk due to patent expirations in the U.S. from 2019 to 2028. According to the data, in 2026, one billion U.S. dollars are expected to be at risk due to loss of exclusivity. Sales losses due to patent expiration will become more significant for biologic drugs than for small molecules drugs.
Small molecule sales at risk due to patent expirations in the U.S. from 2019 to 2028
(in billion U.S. dollars)
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Association for Accessible Medicines, & IQVIA. (February 6, 2024). Small molecule sales at risk due to patent expirations in the U.S. from 2019 to 2028 (in billion U.S. dollars) [Graph]. In Statista. Retrieved January 18, 2025, from https://www.statista.com/statistics/869784/projected-sales-at-risk-due-to-loss-of-exclusivity/?__sso_cookie_checker=failed
Association for Accessible Medicines, und IQVIA. "Small molecule sales at risk due to patent expirations in the U.S. from 2019 to 2028 (in billion U.S. dollars)." Chart. February 6, 2024. Statista. Accessed January 18, 2025. https://www.statista.com/statistics/869784/projected-sales-at-risk-due-to-loss-of-exclusivity/?__sso_cookie_checker=failed
Association for Accessible Medicines, IQVIA. (2024). Small molecule sales at risk due to patent expirations in the U.S. from 2019 to 2028 (in billion U.S. dollars). Statista. Statista Inc.. Accessed: January 18, 2025. https://www.statista.com/statistics/869784/projected-sales-at-risk-due-to-loss-of-exclusivity/?__sso_cookie_checker=failed
Association for Accessible Medicines, and IQVIA. "Small Molecule Sales at Risk Due to Patent Expirations in The U.S. from 2019 to 2028 (in Billion U.S. Dollars)." Statista, Statista Inc., 6 Feb 2024, https://www.statista.com/statistics/869784/projected-sales-at-risk-due-to-loss-of-exclusivity/?__sso_cookie_checker=failed
Association for Accessible Medicines & IQVIA, Small molecule sales at risk due to patent expirations in the U.S. from 2019 to 2028 (in billion U.S. dollars) Statista, https://www.statista.com/statistics/869784/projected-sales-at-risk-due-to-loss-of-exclusivity/?__sso_cookie_checker=failed (last visited January 18, 2025)
Small molecule sales at risk due to patent expirations in the U.S. from 2019 to 2028 (in billion U.S. dollars) [Graph], Association for Accessible Medicines, & IQVIA, February 6, 2024. [Online]. Available: https://www.statista.com/statistics/869784/projected-sales-at-risk-due-to-loss-of-exclusivity/?__sso_cookie_checker=failed
